Compare ZSQR & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZSQR | CNTB |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.9M | 140.4M |
| IPO Year | 2020 | 2020 |
| Metric | ZSQR | CNTB |
|---|---|---|
| Price | $1.85 | $0.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.71 |
| AVG Volume (30 Days) | 303.6K | ★ 599.6K |
| Earning Date | 12-01-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.27 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,363,045.00 | $64,000.00 |
| Revenue This Year | N/A | $7,473.67 |
| Revenue Next Year | N/A | $240.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.83 | $0.55 |
| 52 Week High | $16.62 | $3.82 |
| Indicator | ZSQR | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 30.02 | 36.76 |
| Support Level | N/A | N/A |
| Resistance Level | $4.64 | $2.62 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 1.68 | 33.75 |
Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.